These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18409349)

  • 1. [Transferrin microheterogeneity in patients treated by maintenance haemodialysis].
    Formanowicz D; Pietrzak I; Wiktorowicz K
    Przegl Lek; 2007; 64(7-8):483-8. PubMed ID: 18409349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transferrin changes in haemodialysed patients.
    Formanowicz D; Formanowicz P
    Int Urol Nephrol; 2012 Jun; 44(3):907-19. PubMed ID: 21455763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
    Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minor impairment of oral iron absorption in non-diabetic new dialysis patients.
    Tovbin D; Schnaider A; Vorobiov M; Rogachev B; Basok A; Shull P; Novack V; Friger M; Avramov D; Zlotnik M
    J Nephrol; 2005; 18(2):174-80. PubMed ID: 15931645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study.
    Hsu PY; Lin CL; Yu CC; Chien CC; Hsiau TG; Sun TH; Huang LM; Yang CW
    J Nephrol; 2004; 17(5):693-700. PubMed ID: 15593037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reticulocyte hemoglobin content in hemodialysis patients with acute infection.
    Mitsuiki K; Harada A; Miyata Y
    Clin Exp Nephrol; 2004 Sep; 8(3):257-62. PubMed ID: 15480904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
    Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible influence of vitamin D receptor gene polymorphisms on recombinant human erythropoietin requirements in dialysis patients.
    Sezer S; Tutal E; Bilgic A; Ozdemir FN; Haberal M
    Transplant Proc; 2007; 39(1):40-4. PubMed ID: 17275471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring iron status in end-stage renal disease patients on hemodialysis.
    Rafi A; Karkar A; Abdelrahman M
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous iron attenuates postvaccination anti-HBsAg titres after quadruple hepatitis B vaccination in dialysis patients with erythropoietin therapy.
    Liu JH; Liu YL; Lin HH; Yang YF; Kuo HL; Lin PW; Huang CC
    Int J Clin Pract; 2009 Mar; 63(3):387-93. PubMed ID: 18410348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of reticulocyte haemoglobin content as marker of iron deficiency and predictor of response to intravenous iron in haemodialysis patients.
    Kim JM; Ihm CH; Kim HJ
    Int J Lab Hematol; 2008 Feb; 30(1):46-52. PubMed ID: 18190467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2007; 120(6):797-803. PubMed ID: 17391740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin.
    Aggarwal HK; Nand N; Singh S; Singh M; Hemant ; Kaushik G
    J Assoc Physicians India; 2003 Feb; 51():170-4. PubMed ID: 12725261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous iron supplementation in children on hemodialysis.
    Leijn E; Monnens LA; Cornelissen EA
    J Nephrol; 2004; 17(3):423-6. PubMed ID: 15365964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
    Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
    Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reticulocyte response after immediate withdrawal of recombinant human erythropoietin in chronic hemodialysis patients].
    Caramelo C; Soto C; Neira F; López MD; Jiménez S; Albalate M; de Oña R; Llamas P; Deudero JJ
    Nefrologia; 2004; 24(4):351-6. PubMed ID: 15455495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hematological and iron parameters to predict mortality in ESRD].
    Cantaro S; Piva E
    G Ital Nefrol; 2005; 22 Suppl 31():S135-9. PubMed ID: 15786388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients.
    Reuter SE; Faull RJ; Ranieri E; Evans AM
    Nephrol Dial Transplant; 2009 Mar; 24(3):990-6. PubMed ID: 18987259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Is the management of anemia in hemodialysis patients improving in France? Results of the DiaNE study].
    Kessler M; Landais P; Canivet E; Yver L; Bataille P; Brillet G; Commenges B; Koné S
    Nephrol Ther; 2009 Apr; 5(2):114-21. PubMed ID: 19042175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.